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Abstract: Perianal fistulas are a common complication of Crohn’s disease (CD) that has, historically,
been challenging to manage. Despite the strong available evidence that anti-tumor necrosis factor
(anti-TNF) agents are useful in the treatment of perianal fistulizing Crohn’s disease (PFCD), a significant number of these patients do not respond to therapy. The use of therapeutic drug monitoring
(TDM) in patients with CD receiving biologic agents has evolved and is currently positioned as an
important tool to optimize and guide biologic treatment. Considering the treatment of PFCD can
represent a challenge; identifying novel tools to improve the efficacy of current treatments is an
important unmet need. Given its emerging role in other phenotypes of Crohn’s disease, the use of
TDM could also offer an opportunity to enhance the effectiveness of available therapies and improve
outcomes in the subset of patients with PFCD receiving biologics. Overall, there is mounting evidence
that higher anti-TNF drug levels are associated with better rates of “fistula healing”. However, studies
have been limited by their use of subjective outcomes and observational designs. Ultimately, further
interventional, randomized controlled trials looking into the relationship between drug exposure and
fistula outcomes are needed.
Keywords: Crohn’s disease; therapeutic drug monitoring; anti-tumor necrosis factor; perianal fistulas;
infliximab; ustekinumab; vedolizumab; adalimumab
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1. Introduction

Academic Editor: Angelo Viscido

Crohn’s disease (CD) is an increasingly prevalent chronic inflammatory bowel disease
(IBD) characterized by the development of inflammation in the gastrointestinal tract [1,2].
Among those patients with Crohn’s disease, some develop perianal fistulizing Crohn’s
disease (PFCD). This is a debilitating phenotype that can be seen in up to a third of
patients [3–5]. Its incidence increases with distal disease and its presence is associated with
an overall worse prognosis [3,6]. It can lead to significant pain, perineal disfigurement,
and fecal incontinence. Furthermore, patients with severe, refractory disease may also
require proctectomy and permanent ostomy [7]. A multidisciplinary approach that includes
combined medical and surgical therapies guided by radiologic and endoscopic diagnostics
has shown to have a higher success rate in managing this phenotype than medical therapy
alone [8]. Although there are multiple medical options available for the management of
PFCD, most of them are limited in their overall efficacy.
Over the last decade, anti-tumor necrosis factor (anti-TNF) agents, particularly infliximab (IFX), have demonstrated their effectiveness in this subset of patients and have
become first-line medical therapy in the treatment of PFCD. However, as with luminal
Crohn’s disease, a significant fraction of patients do not respond to therapy. This has led
into the investigation of pharmacokinetic mechanisms of non-response, such as low drug
levels and anti-drug antibodies with fistula healing. Observational studies have revealed
limited evidence that the use of TDM in patients with PFCD on biologics may potentially
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have a role in improving outcomes. In this narrative review, we sought to summarize the
current evidence behind those biologic therapies utilized in PFCD while highlighting the
emerging role of TDM in patients presenting with this phenotype.
2. Evidence behind the Current Biologic Therapies Utilized in the Management of
Perianal Fistulizing Crohn’s Disease
Although there is growing evidence supporting the role of biologics in PFCD, there
is a significant gap in knowledge regarding the positioning, optimization, and use of the
biologics that are now available. Within these agents, IFX is one of the most recognized
options due to the availability of randomized controlled trials supporting its efficacy in
this patient population. The exact role of the newer generations of biologics, such as
vedolizumab (VDZ) and ustekinumab (UST), remains less clear [9,10].
The first double-blind, placebo-controlled trial which studied anti-TNFs in PFCD
was published in 1999 by Present et al. [11]. The study included 94 patients who were
randomized to induction therapy with IFX dosed at 5 mg/kg, 10 mg/kg, or placebo
at 0, 2, and 6 weeks. The primary endpoint of the trial was defined as a reduction of 50% or
more in the number of draining fistulas at two or more consecutive study visits, which were
required to be 21 days apart. The resolution of a draining fistula was defined as the lack of
drainage upon gentle finger compression. The authors found that 68% of those patients
receiving IFX at a dose of 5 mg/kg and 56% of those receiving IFX at a dose of 10 mg/kg
achieved this primary endpoint. This rate of effectiveness was significantly higher than
the 26% seen in the group that received placebo. Complete response, defined as absence of
drainage on two consecutive visits, was seen in 55%, 38%, and 13% of patients treated with
IFX 5 mg/kg, IFX 10 mg/kg, and placebo, respectively. The response rate in this initial trial
did not appear dose related, with the 5 mg/kg group having a higher rate of response than
the 10 mg/kg group.
A subsequent multicenter, double-blind, randomized, placebo-controlled trial performed by Sands et al. investigated the efficacy of IFX as a maintenance therapy for
PFCD [12]. In this study, patients received an open label induction regimen of IFX 5 mg/kg
at weeks 0, 2, and 6. Those patients that responded to treatment were then randomized to
continue IFX 5 mg/kg or placebo every 8 weeks for 54 weeks. Response to treatment was
defined as a reduction of at least 50% from baseline in the number of draining fistulas at
weeks 10 and 14 after the induction regimen. The primary outcome was loss of response
through week 54 of treatment defined as: recurrence of draining fistulas, need for additional
or alternate therapy for worsening or persistent (luminal) disease, need for surgery, or
self-discontinuation of the medication by the patient due to lack of efficacy. At the end of
the follow-up, those patients that received IFX therapy had a significantly lower rate of
loss of response when compared to those that received placebo (more than 40 weeks vs.
14 weeks, respectively [p < 0.001]).
What makes these trials unique is that they are among the few randomized controlled
trials investigating a biologic agent for PCFD. However, a considerable limitation is the
subjective nature of the primary endpoint of “fistula closure”, as it was based on the
investigators’ physical evaluation of the patients and did include a more objective endpoint
such as cross-sectional imaging. Additionally, the endpoint of “50% reduction in fistulas
from baseline” was also left to the clinician’s assessment and different clinicians may have
interpreted this endpoint differently. In an ideal scenario, a clinical trial should have a more
objective, centrally read primary outcome. This has been recognized by investigators and a
recent systematic review noted that radiologic outcomes are becoming more increasingly
incorporated into the primary endpoints of trials investigating PFCD [13].
The efficacy of another anti-TNF, adalimumab (ADA), was shown in a sub-group
analysis of the CHARM trial which demonstrated that at week 26 of treatment, complete
fistula closure (defined as closure of all fistulas that were draining at screening visits) was
achieved in 30% in the ADA-treated patients versus 13% of those receiving placebo [14].
This difference remained significant through week 56. Most notably, all the patients that
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achieved complete fistula closure at week 26 remained in remission at week 56. Another
retrospective cohort study conducted in 15 tertiary centers in Spain showed that at 6 months
of therapy, 66% of patients treated with ADA experienced an improvement in complex
fistulas [15]. A particular strength of this study was the use of magnetic resonance imaging
to assess PFCD activity. The authors did find a correlation between clinical and radiological
disease activity (κ = 0.68). A more recent meta-analysis consisting of seven studies and
379 patients found that 36% (95% CI: 0.31–0.41) of patients receiving ADA had obtained
complete fistula closure (defined as no draining fistulas on examination) at follow up
periods ranging from 4 to 56 weeks [16].
Unlike IFX and ADA, the role of other biologics, such as certolizumab-pegol, VDZ, and
UST, is less certain. Sub-group analysis of larger studies such as the GEMINI II trial and
registry data show that a higher percentage of patients on VDZ experience fistula closure
when compared to placebo [17–23]. This association is supported by the recent ENTERPRISE
trial, a phase 4, randomized, double- blind, multicenter trial which evaluated the efficacy of
VDZ in PFCD in patients with CD with 1-3 MRI-confirmed perianal fistulas [10]. One arm
received VDZ, 300 mg IV at weeks 0, 2, 6, 14, and 22, while the other arm received the same
regimen with an additional VDZ dose at week 10. At week 30, 53.6% of all subjects included in
the study achieved the primary endpoint of having greater than a 50% decrease from baseline
in the number of draining perianal fistulae (defined as no longer draining despite gentle
finger compression). The arm randomized to receive an extra dose of VDZ at week 10 did not
have better outcomes when compared to the arm that had the standard treatment regimen.
However, despite the strength of being a prospective study, the generalizability of this trial
was limited due to its small sample size and lack of a placebo-arm.
Regarding ustekinumab, the recent BioLAP multicenter retrospective study showed
that, out of patients who had been received ustekinumab (UST) therapy for at least 3 months,
38.5% with active PFCD at initiation of treatment reached the endpoint of “clinical success”
at 6 months [9]. Clinical success was defined by the absence of draining purulent material
as determined by a clinician, as well as not having a need for new medical or surgical
intervention. This study also showed that, among patients with a history of PFCD that was
inactive at the time of ustekinumab initiation, only 22% had a recurrence of perianal disease.
Despite the encouraging results, the study is limited by its poor definition of fistulas and
retrospective design.
3. Therapeutic Drug Monitoring: Current Application in Inflammatory Bowel Disease
Despite the proven efficacy of biologics in IBD, up to 30% experience primary nonresponse, while approximately another 40% develop secondary non-response over time,
requiring dose optimization or the need to switch therapy. The development of immunogenicity against the drug and/or sub-optimal drug levels can explain a significant number
of therapeutic failures [24].
The advent of therapeutic drug monitoring, defined as the evaluation of serum drug
concentrations and the presence/titers of anti-drug antibodies at a specific point in time
has helped clinicians guide treatment by allowing them to identify those patients that
may experience a benefit with dose optimization versus those where increase the dose
is likely futile and should switch therapies and/or strategies. Numerous studies have
demonstrated that higher serum biologic concentrations are associated with improved
objective therapeutic outcomes, such as mucosal healing and normalization of inflammatory
markers [25–32]. However, these studies have shown an association and not causation.
Drug levels may be lower in patients with a higher disease burden and higher drug
clearance. An important debate has been regarding the use of “pro-active” TDM of antiTNFs, where drug doses are adjusted with the goal of maintaining a specific drug threshold,
independently of disease activity [33,34]. The results have been conflicting, mainly due
to the heterogenicity in the characteristics of patients, potential difference in target drug
levels, and limitations in study design, among others.
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4. Anti-Tumor Necrosis Factor Drug Levels and Outcomes in Perianal Fistulizing
Crohn’s Disease
Studies looking into TDM and the association of anti-TNF drug levels and drug efficacy
have also been conducted in sub-group of CD disease patients with specific phenotypes
(Table 1). Emerging evidence has shown a strong association between higher anti-TNF
drug levels and fistula healing in PFCD. A retrospective cohort study by Davidov et al.
included 36 patients with active PFCD who received IFX at a standard dose of 5 mg/kg at
weeks 0, 2, and 6, followed by every 8 weeks and looked at the association of drug levels
and clinical response at week 14, defined as “decreased drainage of fistulas as reported by
the patient and verified by a physician” [35]. The authors found that the group of patients
with “clinical response” had higher median trough IFX levels when compared to those
that did not (week 2, 20 vs. 5.6 µg/mL, p = 0.0001; week 6, 13.3 vs. 2.55 µg/mL p = 0.0001;
and week 14, 4.1 vs. 0.14 µg/mL, p = 0.01). Specifically, IFX serum levels ≥ 9.25 µg/mL
at Week 2 and ≥7.25 µg/mL at Week 6 were noted to be best associated with response
to treatment at week 14. Despite its positive findings, this study had several limitations
including a small sample size, retrospective study design, lack of follow up fistula imaging
on most patients and the inherent subjective nature in which the outcomes were measured.
A larger retrospective study performed by Yarur et al. included 117 PFCD patients
with an active fistula and showed that, at a median of 29 weeks of IFX therapy, those with
healing of perianal fistula (defined as absence of drainage after gentle compression) had
higher trough IFX concentrations in comparison to those with active disease (15.8 µg/mL
versus 4.4 µg/mL; p < 0.001) [36]. Quartile analysis of serum IFX concentrations showed
that IFX levels > 10.1 µg/mL and >20.3 µg/mL were associated with three- and eightfold chance of fistula healing, respectively. Additionally, patients with fistula healing
had a lower likelihood of having serum anti-IFX antibodies (OR, 0.04; 95% CI, 0.004–0.3,
p < 0.0001) and IFX levels ≥ 10.1 mcg/mL were significantly associated with fistula closure
(OR, 2.9; 95% CI, 1.1–8.7, p < 0.036). Notably, a subset of included patients achieved
fistula healing only at levels of ≥20 mcg/mL, which potentially supports the approach
of optimizing drug levels to this threshold prior to abandoning therapy in patients who
have not experienced fistula healing at lower trough IFX levels. The study was limited
given its retrospective study design and due to its failure in distinguishing simple vs.
complex fistulas. As in other TDM studies, the results only proved an association and
not causation. A particular strength of the study was that it contained the largest sample
size of any study investigating this topic and did include patients who had received dose
optimization/escalation, opening the possibility to assess the rates of fistula healing on
those patients with a high IFX exposure.
Strik et al. added to this growing body of literature with a retrospective study investigating ADA in addition to IFX in the treatment of PCFD [37]. Patients maintained
on these anti-TNFs were separated into two groups based on the status of their fistulas
(actively draining or non-draining). Fistula closure was defined as the absence of purulent
discharge upon gentle finger compression and/or fistula closure on MRI of the pelvis. The
authors found that serum trough levels were significantly higher in patients with fistula
closure as compared to those with active drainage in both IFX (6.0 µg/mL vs. 2.3 µg/mL;
p < 0.001) and ADA groups (7.4 µg/mL vs. 4.8 µg/mL; p = 0.003). An IFX trough level
of ≥5 µg/mL and an ADA trough level ≥ 5.9 was significantly associated with perianal
fistula closure. For IFX, higher closure rates were seen in those naïve to biologics and with
combination therapy as opposed to the patients receiving monotherapy. In the ADA group,
the treatment duration and combined use of a seton was associated with higher rates of
fistula closure. The objectivity provided by MRI (as opposed to the subjectivity of physical
exam) was a particular strength of this study.
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Table 1. Studies demonstrating association between increased biologic drug levels with fistula healing in PFCD.
Author (Year)

Population

No. of Subjects

Anti-TNF

Primary Outcome

Drug Concentration in
Active Fistulas (µg/mL)

Drug Concentration in
Healed/Closed Fistulas
(µg/mL)

Strengths

Limitations

Davidov et al. [35]
(2016)

Adults

36

IFX

Decrease in drainage
of fistulas

Week 2: 5.6 µg/mL
Week 6: 2.55 µg/mL
Week 14: 0.14 µg/mL

Week 2: 20.0 µg/mL
Week 6: 13.3 µg/mL
Week 14: 4.1 µg/mL

Similar demographics
in both groups

small sample size, no
imaging, subjective outcome

Yarur et al. [36]
(2016)

Adults

117

IFX

absence of drainage

4.4 µg/mL

15.8 µg/mL

Large sample size

Retrospective, didn’t
distinguish simple vs.
complex fistulas

Strik et al. [37]
(2019)

Adults

47 IFX
19 ADA

IFX
ADA

absence of discharge
upon gentle finger
and/or fistula closure
on MRI

IFX: 2.3 µg/mL
ADA: 4.8 µg/mL

IFX: 6.0 µg/mL
ADA: 7.4 µg/mL

Assessment
with imaging

Retrospective, didn’t
distinguish simple vs.
complex fistulas

Plevris et al. [38]
(2020)

Adults

29 IFX
35 ADA

IFX
ADA

Absence of drainage

IFX: 3.2 µg/mL
ADA: 2.7 µg/mL

IFX: 8.1 µg/mL
ADA: 12.6 µg/mL

Secondary outcome of
fistula closure

Retrospective, no imaging

Et Matary et al. [39]
(2019)

Pediatric

27

IFX

Decrease in drainage
of fistulas

5.4 ug/mL

12.7 ug/mL

Prospective study

Small sample size

Ruemmele et al. [40]
(2018)

Pediatric

36

ADA

Closure of baseline
fistulas or decrease in
number by ≥50%

Week 16: 7.0 ug/mL
Week 52: 6.1 ug/mL

Week 16: 7.4 ug/mL
Week 52: 10.0 ug/mL

Well defined endpoints

Not powered to detect
statistical difference, not
randomized, not
placebo controlled

Papamichael et al. [41]
(2021)

Adults

Induction group
n = 282
maintenance
group n = 139

IFX

Fistula response:
reduction of at least
50% of draining fistulas
from baseline

No Response: 4.0 µg/mL

Response: 5.7 µg/mL

large sample size,
the use of
stringent endpoints

No imaging assessment of
fistula, not randomized

De Gregario et al. [42]
(2021)

Adults

117 IFX
76 ADA

IFX

Radiologic healing
(inflammatory subscore
≤6 on Van
Assche Index)

IFX: 3.9 µg/mL
ADA: 6.2 µg/mL

IFX: 6.0 µg/mL
ADA: 9.1 µg/mL

Use of radiographic
parameters

Not placebo controlled,
not randomized

Schwartz, D. A et al. [10]
(2021)

Adults

VDZ (16)
VDZ +10 (18)

VDZ

≥50% decrease from
baseline in the number
of draining perianal
fistulae at week 30

~33 µg/mL
(pooled trough conc.
week 10)

~28 µg/mL
(pooled trough conc.
week 10)

Multicenter- RCT,
use of MRI

Small sample size,
no placebo arm

J. Clin. Med. 2022, 11, 1813

6 of 12

Plevris et al. also investigated both IFX and ADA for PFCD with a retrospective crosssectional study including 64 patients on maintenance therapy for at least 24 weeks [38].
Drug levels were measured ±4 weeks of the clinical assessment of the fistula. IFX drug
and antibody levels were measured at trough, while for ADA drug and antibody levels
were measured at any time between doses. The primary outcome was perianal fistula
healing (defined as the absence of drainage) and the secondary outcome was perianal
fistula closure (defined as no external skin opening in the peri-anal area). Patients with
fistula healing had higher levels of anti-TNF trough levels vs. those without fistula healing
(ADA: 12.6 vs. 2.7 µg/mL, p < 0.01; IFX: 8.1 vs. 3.2 µg/mL, p < 0.01). Patients with fistula
closure also had significantly higher anti-TNF trough levels vs. those without fistula closure
(ADA: 14.8 vs. 5.7 µg/mL, p < 0.01; IFX: 8.2 vs. 3.2 µg/mL, p < 0.01). Receiver operating
characteristic analysis revealed a cutoff of ≥6.8 µg/mL for fistula healing and ≥9.8 µg/mL
for fistula closure in patients receiving ADA and an optimum trough of ≥7.1 µg/mL for
both fistula healing and closure for IFX. Again, the retrospective design of the study and
lack of objective evaluation of the fistulas with imaging were limitations of this study.
El-Matary et al. performed a multicenter prospective cohort study including 27 pediatric patients (<17 years) with PCFD who were treated with IFX and who had serum trough
drug titers measured before the fourth dose [39]. The median IFX pre-fourth dose level in
the responders (defined as a decrease in drainage of fistulas) was 12.7 ug/mL, compared
with 5.4 ug/mL in the group with no response (p = 0.02). A particular strength of this study
was its prospective study design; however, the small sample size, lack of long term follow
up, and the subjective primary outcome were notable limitations.
In a post-hoc analysis, Ruemmele et al. performed a sub-analysis of the data from
the IMAgINE 1 and IMAgINE 2 trials [40]. These trials cumulatively followed pediatric
patients for 292 weeks and demonstrated the efficacy of ADA in fistula closure and fistula
improvement (as defined as closure of all baseline fistulas or decrease in number by ≥50%,
respectively, for at least two consecutive visits). The patients were randomly assigned
to receive either high dose ADA (defined as 20 mg every other week [EOW] or 40 mg
EOW if >40 kg) or standard doses (defined as 10 mg every other week [EOW] or 20 mg
EOW if >40 kg). Although the concentration of ADA in patients with fistula closure
trended slightly higher than those not achieving fistula closure at weeks 16 (7.4 µg/mL
vs. 7.0 µg/mL) and 52 (10 µg/mL vs. 6.1 µg/mL), there was no statistically significant
difference between the two groups. While this contradicted the adult studies and findings
of El Matary et al., the limited study was not powered to detect statistical differences
between treatment groups, did not have a placebo-arm, and lacked objective assessment of
fistula closure with pelvic MRI.
The most recent evidence supporting optimizing post-induction IFX levels arises
from a post hoc analysis of the ACCENT-II trial by Papamichael et al., which evaluated
patients with fistulizing CD receiving induction and maintenance infliximab therapy [41].
Measured outcomes included fistula response (defined as a reduction of at least 50% of
draining fistulas from baseline), complete fistula remission (defined as absence of draining
fistulas), CRP normalization (defined as a CRP level ≤5 mg/L), and, finally, a composite
outcome of both complete fistula remission combined with CRP normalization at week
14 and week 54. Higher week 14 IFX concentrations were independently associated with
week 14 fistula response (odds ratio [OR]: 1.16; 95% confidence interval [CI]: 1.02–1.32;
p = 0.019), and composite remission (OR: 2.32; 95% CI: 1.55–3.49; p < 0.001). Higher
week 14 IFX concentrations were also independently associated with week 54 composite
remission (OR: 2.05; 95% CI: 1.10–3.82; p = 0.023). ROC curve analysis identified an IFX concentration of ≥9.6 µg/mL at week 6 to be associated with complete fistula response at week
54. Most notably, the analysis revealed that IFX concentrations of ≥ 26.1 µg/mL at week
6 and ≥8.7 µg/mL at week 14 were associated with the highest rates of early composite
remission (36% and 48%, respectively). Furthermore, IFX concentrations ≥ 11.3 µg/mL at
week 14 were associated with the highest rate of long-term composite remission. These findings are interesting and open the debate on whether proactively increasing infliximab doses
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early on therapy may improve short- and long-term outcomes. Randomized controlled
trials are warranted to support this hypothesis.
A cross-sectional retrospective study by De Gregario et al. added a more objective
viewpoint to existing evidence by documenting the association of anti-TNF levels and radiologic fistula outcomes [42]. This study included 193 patients with PFCD on maintenance
IFX or ADA who had drug levels checked within 6 months of a pelvic MRI. Radiologic disease activity was scored using the Van Assche Index (VAI) with an inflammatory subscore
calculated using multiple indices: T2-weighted imaging hyperintensity, collections > 3 mm
diameter, and rectal wall involvement. The primary endpoint was radiologic healing (inflammatory subscore ≤ 6). The secondary endpoint was radiologic remission (inflammatory
subscore = 0). Patients with radiologic healing had higher median drug levels compared
with those with active disease (IFX 6.0 vs. 3.9 µg/mL; ADA 9.1 vs. 6.2 µg/mL; p < 0.05 for
both). Patients with radiologic remission also had higher median drug levels compared
with those with active disease (IFX 7.4 vs. 3.9 µg/mL; p < 0.05; ADA 9.8 vs. 6.2 µg/mL;
p = 0.07). This study is unique because most of the other retrospective trials had a largely
subjective definition of fistula healing and lacked the objectivity provided by imaging
studies. Despite this distinguishing attribute, the study does have multiple limitations. The
VAI is not a validated scoring index and since the imaging was not centrally reviewed,
there was inherent risk of variability and bias from the different radiologists interpreting
the images.
Prospective randomized studies looking into the association of fistula healing and
VDZ and UST serum levels are scarce. Data from the ENTERPRISE study did show
that, in the group that received VDZ with an extra dose at week 10, patients with fistula
healing had a higher pooled VDZ trough concentration between weeks 6 and 22 of the
study. However, since more patients terminated treatment early in this group, and given
the overall small sample size, the authors were unable to draw a definitive conclusion
regarding the relationship between VDZ drug exposure and treatment response [10].
5. Discussion
The management of PFCD typically combines a medical and surgical approach. Biologics, especially anti-TNF agents, have demonstrated an important role in the treatment
of PFCD. The current evidence supports an association between higher IFX and ADA
serum drug levels with higher rates of fistula healing. Considering these findings, it would
be tempting for many clinicians to assume that increasing drug doses could improve
outcomes. However, randomized controlled trials are needed to prove this hypothesis.
The lower drug levels seen in those patients that do not achieve fistula healing could
potentially be explained by a higher inflammatory burden and higher drug clearance. The
current literature is also significantly limited by deficits in study design, low sample sizes,
variability in patient selection, failure to stratify different types of fistulas, and lack of
objective endpoints.
One ongoing interventional randomized controlled study by Gu et al. may offer a
better insight on how TDM could effectively be used in PFCD [43]. The PROACTIVE trial
(Prospective randomized controlled trial of adults with perianal fistulizing Crohn’s disease
and optimized therapeutic IFX levels) is enrolling patients with active PFCD randomized
to either a proactive TDM group or standard dosing group with a 54 week follow up
period. The proactive TDM group will have IFX dosing optimized to target higher trough
concentrations at various time points (≥25 µg/mL at week 2, ≥20 µg/mL at week 6 and
≥10 µg/mL during maintenance therapy). The standard arm will be treated with the
standard 5 mg/Kg dose of IFX at weeks 0, 2, and 6 weeks followed by every 8 weeks. The
primary outcome of the study will be fistula healing at week 32 and secondary outcomes
include fistula closure, fistula healing, radiological fistula healing, economic costs, and
patient-reported outcomes. The addition of a radiologic outcome will serve to support the
more subjective, clinical primary outcome. This is helpful as many of the studies reviewed
lack this level of objectivity.
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This randomized trial may also help prove causation and not just correlation when it
comes to increased drug levels and improved fistula healing. Currently there is a strong
association between the two, but the decreased serum levels in non-healing fistulas may be
due to other factors, such as increased drug clearance and a higher inflammatory burden.
This concern is supported by the ATLAS study which showed that there are also localized
tissue factors that play a role in variations of local and systemic drug levels [44]. This study
was unique in that it not only reported an accurate measurement of tissue levels of anti-TNF
drug in luminal Crohn’s disease, but also found that these levels correlated well with the
serum drug levels. The key finding of the study suggested that areas of severe luminal
inflammation act as a ‘sink’ for the drug and resulted in diminished localized tissue drug
levels. This drop in specific tissue drug levels may, thereby, be reducing its concentration
and, therefore, efficacy in another area of inflammation, thus, leading to a mismatch in
serum and tissue drug levels in these patients. The authors proposed this as an explanation
for why patients with “normal” serum drug levels may still have uncontrolled disease and
suggested that increasing these levels may result in improved outcomes. More recently, the
same authors observed that increased serum infliximab levels were also associated with
improved fistula healing in PFCD as compared to those with luminal disease. This leads to
the question of possibly insufficient drug concentrations within the perianal tissues as a
possible mechanistic explanation in treatment failure.
This question was recently explored by a pilot study assessing the fistula tissue
levels of anti-TNF agents (infliximab and adalimumab) by use of ultraperformance liquid
chromatography-mass spectrometry [45]. The authors obtained tissue samples from the
fistula tracts of seven patients with Crohn’s perianal disease (five patients on adalimumab
and two patients on infliximab) on maintenance treatment and compared tissue drug
activity to negatives controls and spiked positive controls. They observed a lack of drug
activity in all fistula samples taken from Crohn’s on maintenance therapy despite activity
in positive controls. This raises the question on how tissue and serum pharmacokinetics
are related and what role that the administration of higher doses may have on outcomes.
Higher dosing sub-groups do not always have better outcomes, as seen in the study
cited above by Present et al. [11]. Although increasing dose and shortening intervals between doses has been shown to increase drug levels and clinical response in luminal disease
there is significant pharmacologic variation between individuals. Patient characteristics
such as high body weight, low albumin, and presence of ATI have been documented factors
in increasing clearance of serum anti-TNF and leading to decreased serum levels [46]. There
is also evidence that suggests shortening dose intervals may be a better way in increasing serum drug concentrations as opposed to simply increasing the medication dosage,
especially in patients with low serum albumin levels. The development of an optimal,
individualized dosing strategy for PFCD must consider all of these factors.
Another major question that warrants further investigation is the role that non-antiTNF biologics can play in the treatment algorithm of PFCD and how the use of TDM for
those drugs may help to optimize therapy in this patient population. Aside from observational evidence showing a possible dose-related response, there are limited randomized
controlled data to guide the incorporation of these agents into the management of PFCD.
A recent multicenter randomized, controlled trial (ENTERPRISE) supported the use of
VDZ in the treatment algorithm of PFCD by demonstrating a 53.6% pooled success rate
in achieving the primary endpoint of having greater than a 50% decrease from baseline
in the number of draining perianal fistulae [10]. This study also boasted a 71.4% fistula
closure rate during the 30 week follow up period. Additionally, patients that responded to
treatment trended towards a higher VDZ trough concentration between weeks 6 and 22 in
the study arm that administered an extra dose of VDZ at week 10. However, despite these
significant findings, the study was substantially limited by its lack of placebo-arm, small
sample size (n = 38) and inability to support the findings with radiographic data.
No randomized controlled trials have assessed the efficacy of UST in PFCD; however,
the recently published BioLAP multicenter, retrospective study showed that, out of patients
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who had been received UST therapy for at least 3 months, 38.5% with active PFCD at
initiation of treatment reached the endpoint of “clinical success” at 6 months [9]. The
interpretation of these data is limited by the subjective definition of the main outcome as it
relied on a physician’s interpretation of fistula drainage and not a more objective outcome
such as radiographic healing. Additionally, due to the retrospective nature of this study,
the authors were not able to assess the relationship between serum UST levels and fistula
response. They did find, however, that the lack of optimization of UST was associated
with improved outcomes, but this was attributed to the refractory nature of disease in
those that required aggressive drug optimization. Given this potential confounder and
lack of drug level comparison between responders and non-responders in this study, the
role of TDM with UST and PFCD remains unclear. Although this study shows a definite
correlation between UST use and fistula healing, the exact role of UST in the treatment of
PFCD remains uncertain and further prospective, randomized studies are needed.
Lastly, although this review focuses on the optimization of medical therapy with
TDM, it is important to remember the crucial role of surgery in the management of PFCD.
A combined medical and surgical approach in managing PFCD has shown to have better outcomes than medical therapy alone [47–49]. Irrespective of the prescribed medical
therapies, individualized interventions, such as abscess drainage, seton placement, fistulectomy, fistulotomy, ligation, and advancement flaps, may be needed and, therefore, surgical
consultation should be obtained to further guide these decisions.
6. Conclusions
PFCD is a challenging and debilitating phenotype of CD that has been historically
difficult to manage. Anti-TNF agents, especially IFX, have emerged as the cornerstone of
medical management in these patients. High quality evidence supporting the efficacy of
most biologics and the potential role of TDM in PFCD is limited. Overall, the evidence
supports that higher anti-TNF drug levels correlate with higher efficacy; however, no
high quality, interventional data are available. This is partly because performing high
quality clinical trials in PFCD can be challenging and costly. Moreover, conducting, and
interpreting TDM studies impose their own challenges. Drug level concentrations may
vary between laboratories and assays, which limits the extrapolation and comparison
of results. Moreover, endpoints may vary across studies and patient demographics and
selection may also complicate the interpretation of the data. Despite these challenges,
further investigations in TDM are undergoing and may lead to a future of individualized
and optimized management in patients not only with PFCD, but with IBD in general.
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